Next Article in Journal
The Clinical Impact of MicroRNA-21 in Low Rectal Cancer Treated with High-Dose Chemoradiotherapy in the Organ Preserving Setting
Next Article in Special Issue
Disease-Related Knowledge in New Zealand Children with Inflammatory Bowel Disease (IBD) and Their Parents
Previous Article in Journal / Special Issue
Making Decisions about Dietary Therapy in Inflammatory Bowel Disease
Article

20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease

1
Division of Circulation and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, 5200, Kibana, Kiyotakecho, Miyazaki 889-1692, Japan
2
Peptide Institute, Inc., 7-2-9 Saito-Asagi, Ibaraki-shi, Osaka 567-0085, Japan
3
Frontier Science Research Center, University of Miyazaki, 5200, Kibana, Kiyotakecho, Miyazaki 889-1692, Japan
*
Author to whom correspondence should be addressed.
Gastrointest. Disord. 2020, 2(4), 366-377; https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040033
Received: 15 September 2020 / Revised: 2 October 2020 / Accepted: 4 October 2020 / Published: 7 October 2020
Human adrenomedullin (AM), a hypotensive peptide, also has anti-colitis activity. We prepared a polyethylene glycol (PEG) ylated form of AM through the conjugation of PEG-AM (1–15) and AM (15–52). Highly pure monomeric 20 kDa PEG-AM (20kPEG-AM) stimulated cyclic adenosine monophosphate production in HEK-293 cells stably expressing the type 1 AM receptor in a dose-dependent manner. The half-life of 20kPEG-AM was 7.4 h following subcutaneous administration in mice. We assessed the anti-colitis effect of subcutaneous 20kPEG-AM administration in the dextran sodium sulfate murine colitis model. Single and double subcutaneous injection of 20kPEG-AM significantly reduced total inflammation scores. These results suggest that 20kPEG-AM is a promising therapeutic candidate for the treatment of human inflammatory bowel diseases. View Full-Text
Keywords: adrenomedullin; polyethylene glycol; inflammatory bowel disease; colitis; dextran sulfate adrenomedullin; polyethylene glycol; inflammatory bowel disease; colitis; dextran sulfate
Show Figures

Graphical abstract

MDPI and ACS Style

Miki, G.; Kuroishi, N.; Tokashiki, M.; Nagata, S.; Tamura, M.; Yoshiya, T.; Yoshizawa-Kumagaye, K.; Ashizuka, S.; Kato, J.; Yamasaki, M.; Kitamura, K. 20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease. Gastrointest. Disord. 2020, 2, 366-377. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040033

AMA Style

Miki G, Kuroishi N, Tokashiki M, Nagata S, Tamura M, Yoshiya T, Yoshizawa-Kumagaye K, Ashizuka S, Kato J, Yamasaki M, Kitamura K. 20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease. Gastrointestinal Disorders. 2020; 2(4):366-377. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040033

Chicago/Turabian Style

Miki, Goro, Nobuko Kuroishi, Mariko Tokashiki, Sayaka Nagata, Masaji Tamura, Taku Yoshiya, Kumiko Yoshizawa-Kumagaye, Shinya Ashizuka, Joji Kato, Motoo Yamasaki, and Kazuo Kitamura. 2020. "20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease" Gastrointestinal Disorders 2, no. 4: 366-377. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040033

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop